These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

6005 related articles for article (PubMed ID: 19692680)

  • 1. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.
    Mok TS; Wu YL; Thongprasert S; Yang CH; Chu DT; Saijo N; Sunpaweravong P; Han B; Margono B; Ichinose Y; Nishiwaki Y; Ohe Y; Yang JJ; Chewaskulyong B; Jiang H; Duffield EL; Watkins CL; Armour AA; Fukuoka M
    N Engl J Med; 2009 Sep; 361(10):947-57. PubMed ID: 19692680
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS).
    Fukuoka M; Wu YL; Thongprasert S; Sunpaweravong P; Leong SS; Sriuranpong V; Chao TY; Nakagawa K; Chu DT; Saijo N; Duffield EL; Rukazenkov Y; Speake G; Jiang H; Armour AA; To KF; Yang JC; Mok TS
    J Clin Oncol; 2011 Jul; 29(21):2866-74. PubMed ID: 21670455
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy according to blind independent central review: Post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC.
    Wu YL; Saijo N; Thongprasert S; Yang JC; Han B; Margono B; Chewaskulyong B; Sunpaweravong P; Ohe Y; Ichinose Y; Yang JJ; Mok TS; Young H; Haddad V; Rukazenkov Y; Fukuoka M
    Lung Cancer; 2017 Feb; 104():119-125. PubMed ID: 28212993
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase III, randomized, open-label, first-line study in Asia of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer: evaluation of patients recruited from mainland China.
    Wu YL; Chu DT; Han B; Liu X; Zhang L; Zhou C; Liao M; Mok T; Jiang H; Duffield E; Fukuoka M
    Asia Pac J Clin Oncol; 2012 Sep; 8(3):232-43. PubMed ID: 22897752
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cetuximab plus carboplatin and paclitaxel with or without bevacizumab versus carboplatin and paclitaxel with or without bevacizumab in advanced NSCLC (SWOG S0819): a randomised, phase 3 study.
    Herbst RS; Redman MW; Kim ES; Semrad TJ; Bazhenova L; Masters G; Oettel K; Guaglianone P; Reynolds C; Karnad A; Arnold SM; Varella-Garcia M; Moon J; Mack PC; Blanke CD; Hirsch FR; Kelly K; Gandara DR
    Lancet Oncol; 2018 Jan; 19(1):101-114. PubMed ID: 29169877
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.
    Maemondo M; Inoue A; Kobayashi K; Sugawara S; Oizumi S; Isobe H; Gemma A; Harada M; Yoshizawa H; Kinoshita I; Fujita Y; Okinaga S; Hirano H; Yoshimori K; Harada T; Ogura T; Ando M; Miyazawa H; Tanaka T; Saijo Y; Hagiwara K; Morita S; Nukiwa T;
    N Engl J Med; 2010 Jun; 362(25):2380-8. PubMed ID: 20573926
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized phase II study of concurrent versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer with sensitive EGFR mutations: NEJ005/TCOG0902.
    Sugawara S; Oizumi S; Minato K; Harada T; Inoue A; Fujita Y; Maemondo M; Yoshizawa H; Ito K; Gemma A; Nishitsuji M; Harada M; Isobe H; Kinoshita I; Morita S; Kobayashi K; Hagiwara K; Kurihara M; Nukiwa T
    Ann Oncol; 2015 May; 26(5):888-894. PubMed ID: 25669832
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial.
    Schuler M; Yang JC; Park K; Kim JH; Bennouna J; Chen YM; Chouaid C; De Marinis F; Feng JF; Grossi F; Kim DW; Liu X; Lu S; Strausz J; Vinnyk Y; Wiewrodt R; Zhou C; Wang B; Chand VK; Planchard D;
    Ann Oncol; 2016 Mar; 27(3):417-23. PubMed ID: 26646759
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial.
    Soria JC; Wu YL; Nakagawa K; Kim SW; Yang JJ; Ahn MJ; Wang J; Yang JC; Lu Y; Atagi S; Ponce S; Lee DH; Liu Y; Yoh K; Zhou JY; Shi X; Webster A; Jiang H; Mok TS
    Lancet Oncol; 2015 Aug; 16(8):990-8. PubMed ID: 26159065
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.
    Wu YL; Zhou C; Hu CP; Feng J; Lu S; Huang Y; Li W; Hou M; Shi JH; Lee KY; Xu CR; Massey D; Kim M; Shi Y; Geater SL
    Lancet Oncol; 2014 Feb; 15(2):213-22. PubMed ID: 24439929
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor response and health-related quality of life in clinically selected patients from Asia with advanced non-small-cell lung cancer treated with first-line gefitinib: post hoc analyses from the IPASS study.
    Wu YL; Fukuoka M; Mok TS; Saijo N; Thongprasert S; Yang JC; Chu DT; Yang JJ; Rukazenkov Y
    Lung Cancer; 2013 Aug; 81(2):280-7. PubMed ID: 23540718
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quality of life with gefitinib in patients with EGFR-mutated non-small cell lung cancer: quality of life analysis of North East Japan Study Group 002 Trial.
    Oizumi S; Kobayashi K; Inoue A; Maemondo M; Sugawara S; Yoshizawa H; Isobe H; Harada M; Kinoshita I; Okinaga S; Kato T; Harada T; Gemma A; Saijo Y; Yokomizo Y; Morita S; Hagiwara K; Nukiwa T
    Oncologist; 2012; 17(6):863-70. PubMed ID: 22581822
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reasons for response differences seen in the V15-32, INTEREST and IPASS trials.
    Saijo N; Takeuchi M; Kunitoh H
    Nat Rev Clin Oncol; 2009 May; 6(5):287-94. PubMed ID: 19390555
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gefitinib Versus Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in
    Noronha V; Patil VM; Joshi A; Menon N; Chougule A; Mahajan A; Janu A; Purandare N; Kumar R; More S; Goud S; Kadam N; Daware N; Bhattacharjee A; Shah S; Yadav A; Trivedi V; Behel V; Dutt A; Banavali SD; Prabhash K
    J Clin Oncol; 2020 Jan; 38(2):124-136. PubMed ID: 31411950
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial.
    Reck M; Mok TSK; Nishio M; Jotte RM; Cappuzzo F; Orlandi F; Stroyakovskiy D; Nogami N; Rodríguez-Abreu D; Moro-Sibilot D; Thomas CA; Barlesi F; Finley G; Lee A; Coleman S; Deng Y; Kowanetz M; Shankar G; Lin W; Socinski MA;
    Lancet Respir Med; 2019 May; 7(5):387-401. PubMed ID: 30922878
    [TBL] [Abstract][Full Text] [Related]  

  • 16. First-line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in East Asian patients with locally advanced or metastatic non-squamous non-small cell lung cancer: a randomised, phase 3 trial.
    Yang JC; Kang JH; Mok T; Ahn MJ; Srimuninnimit V; Lin CC; Kim DW; Tsai CM; Barraclough H; Altug S; Orlando M; Park K
    Eur J Cancer; 2014 Sep; 50(13):2219-30. PubMed ID: 24953333
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination of chemotherapy and gefitinib as first-line treatment for patients with advanced lung adenocarcinoma and sensitive EGFR mutations: A randomized controlled trial.
    Han B; Jin B; Chu T; Niu Y; Dong Y; Xu J; Gu A; Zhong H; Wang H; Zhang X; Shi C; Zhang Y; Zhang W; Lou Y; Zhu L; Pei J
    Int J Cancer; 2017 Sep; 141(6):1249-1256. PubMed ID: 28560853
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epidermal growth factor receptor mutation status in circulating free DNA in serum: from IPASS, a phase III study of gefitinib or carboplatin/paclitaxel in non-small cell lung cancer.
    Goto K; Ichinose Y; Ohe Y; Yamamoto N; Negoro S; Nishio K; Itoh Y; Jiang H; Duffield E; McCormack R; Saijo N; Mok T; Fukuoka M
    J Thorac Oncol; 2012 Jan; 7(1):115-21. PubMed ID: 21900837
    [TBL] [Abstract][Full Text] [Related]  

  • 19. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
    Greenhalgh J; Dwan K; Boland A; Bates V; Vecchio F; Dundar Y; Jain P; Green JA
    Cochrane Database Syst Rev; 2016 May; (5):CD010383. PubMed ID: 27223332
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Health-related quality-of-life in a randomized phase III first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients from Asia with advanced NSCLC (IPASS).
    Thongprasert S; Duffield E; Saijo N; Wu YL; Yang JC; Chu DT; Liao M; Chen YM; Kuo HP; Negoro S; Lam KC; Armour A; Magill P; Fukuoka M
    J Thorac Oncol; 2011 Nov; 6(11):1872-80. PubMed ID: 22011650
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 301.